How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.
Suzanne Shelley
Advertisement
Articles by Suzanne Shelley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
